Tools
Stock profile

BOSTON SCIENTIFIC CORP (BSX)

BSX · Latest close $43.64 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$43.64
As of Nov 18, 2026
Tracked funds holding
10 of 149
2026 Q2 13F filings
Opened / added
3 / 2
vs previous quarter
Trimmed / exited
12
vs previous quarter

BOSTON SCIENTIFIC CORP (BSX) is held by 10 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds opening new positions, 2 funds adding, and 12 funds trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($100.4K bought vs $0 sold). 1 member of Congress reported 5 purchases vs 8 sales. Latest close $43.64 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Aug 25, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $100.4K
Congress
5 buys vs 8 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Maverick Capital · Mirova US · OrbiMed Advisors — 10 tracked funds hold BSX. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $100.4K) vs 0 sales ($0). Latest buy: Aug 25, 2026. Insider trading 1 member of Congress reported buying (5 purchases vs 8 sales). Latest buy: Aug 18, 2026. Politician trading

Often held alongside

Travere Therapeutics, Inc. (TVTX) · NOVO NORDISK A S (NVO) · Praxis Precision Medicines, Inc. (PRAX) · BIOCRYST PHARMACEUTICALS INC (BCRX) · Abivax S.A. (ABVX) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Maverick Capital2.24%5,937,553ADDED (+41.5%) Q3 filed Nov 16
Mirova US1.42%3,101,478ADDED (+40.8%) Q3 filed Nov 5
OrbiMed Advisors1.17%1,483,200TRIMMED (-37.7%) Q3 filed Nov 16
Deerfield Management0.59%1,315,000NEW Q3 filed Nov 16
Causeway Capital Management0.33%720,339NEW Q3 filed Nov 13
Perceptive Advisors0.16%250,000NEW Q3 filed Nov 16
Saturna Capital0.01%17,835TRIMMED (-58.3%) Q3 filed Nov 16
Dodge & Cox Funds<0.01%87,485TRIMMED (-1.6%) Q3 filed Nov 13
Mairs & Power Funds<0.01%9,914TRIMMED (-2.6%) Q3 filed Nov 16
Polen Capital Management<0.01%4,750TRIMMED (-99.2%) Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -0.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

108.1438.922024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

192025Q4: 19 funds2025Q42025Q4

Tracked funds holding this stock, by quarter (2025Q4–2025Q4, 1 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding1,479 of 8,857 filers
Long-only filers among them1,472
Change vs 2026 Q1-171 net · 1,202 entered · 1,373 exited
Shares reported, all filers1,316,504,087
Reported value, all filers$57.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$20.1B
Net income · FY2025$2.9B
Total assets · FY2025$43.7B
Shares outstanding1,449,229,526
Market cap (at latest close)$63.2B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.

Short interest

Shares short · Oct 15, 202640,708,019
Share of shares outstanding2.81%
Days to cover2.59

Shares short at recent settlements — Jul 31, 2026: 22.3M · Aug 14, 2026: 27.6M · Aug 31, 2026: 48.2M · Sep 15, 2026: 46.5M · Sep 30, 2026: 41.4M · Oct 15, 2026: 40.7M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $100.4K), against 0 sales by 0 insiders ($0). Latest buy: Aug 25, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Morano Susan E · 2,040 shares on Aug 25, 2026 · filed Aug 26, 2026$49.22-7.8% (close Aug 27, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Aug 27, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Aug 25, 2026Morano Susan EBuy2,040$49.22$100.4KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Feb 2, 2026MICHAEL F MAHONEYOfficer, Director160,901$15.0MFeb 2, 2026SEC filing
Dec 1, 2025ARTHUR C BUTCHEROfficer17,313$1.8MDec 1, 2025SEC filing
Nov 6, 2025Zane Ellen MDirector2,901$284.2KNov 6, 2025SEC filing
Nov 3, 2025JOSEPH M FITZGERALDOfficer50,000$5.0MNov 3, 2025SEC filing
Oct 28, 2025Zane Ellen MDirector2,901$296.6KOct 28, 2025SEC filing
Oct 27, 2025Zane Ellen MDirector9,990$1.0MOct 27, 2025SEC filing
Oct 1, 2025JOSEPH M FITZGERALDOfficer50,000$4.9MOct 1, 2025SEC filing
Sep 2, 2025JOSEPH M FITZGERALDOfficer50,000$5.3MSep 2, 2025SEC filing
Aug 1, 2025ARTHUR C BUTCHEROfficer17,313$1.8MAug 1, 2025SEC filing
Aug 1, 2025JOSEPH M FITZGERALDOfficer50,000$5.2MAug 1, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 6, 2026FMR LLCSC 13G/A46,378,258.613.1%Jun 30, 2026SEC filing
May 6, 2026FMR LLCSC 13G/A75,835,683.35.1%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G111,127,2057.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Aug 6, 2025FMR LLCSC 13G/A110,320,937.817.5%Jun 30, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A113,006,6717.6%Mar 31, 2025SEC filing
Apr 7, 2025FMR LLCSC 13G/A141,149,781.519.6%Dec 29, 2023SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (5 purchases vs 8 sales). Bought by Democrats. Latest buy: Aug 18, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Hern, KevinHouseR06Sep 9, 2026$50,001 - $100,000
Cisneros, GilbertHouseD51Aug 18, 2026$1,001 - $15,000
Boozman, JohnSenateR01Jun 4, 2026$1,001 - 15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 365 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (229), Taxation/Internal Revenue Code (169), Medicare/Medicaid (123).

Federal contracts: $162.4M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$27.6M
FY2022$27.3M
FY2023$32.1M
FY2024$23.6M
FY2025$30.0M
FY2026$21.7M

Largest awards collected

Award IDAgencyAmountStart
FA442719CA020Department of Defense$4.7MSep 1, 2019
36C25722P0417Department of Veterans Affairs$4.0MApr 23, 2022
36C25623P0027Department of Veterans Affairs$3.8MOct 1, 2022
36C24823K0018Department of Veterans Affairs$1.7MJan 1, 2022
36C24123P1146Department of Veterans Affairs$1.6MSep 30, 2023

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Financial Screens

· Graham — Sound finances and a long run of profits

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Key figures

· Graham — Current ratio: 1.62 · Straight profitable years: 5 · Debt ratio: — · Latest net income: $2.9B

· Cash Flow (FCF) — Latest FCF: $3.7B · FCF yield: 5.7% · Positive FCF years: 3

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.67 · Operating cash flow: $4.5B · Net income: $2.9B

· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $100.4K · Latest buy: Aug 25, 2026

· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 4 · Buy txns: 6 · Buy value: $9.5M · Latest buy: Aug 25, 2026

· Bought by Members — Members buying: 1 · Buy txns: 5 · Sell txns: 8 · Latest buy: Aug 18, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 1 of the last 40 quarterly lists; latest 2025 Q4, ranked #42 of 50.

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q2, ranked #47 of 50.

· Politician BEST — appeared in 3 of the last 20 quarterly lists; latest 2026 Q2, ranked #36 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together333.3%-1.1%+3.3%-4.4%
Share count tripled (3x)10.0%-25.0%+2.9%-27.9%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold BSX — ranked by lift, the co-holding pattern described in Methodology: Travere Therapeutics, Inc. (TVTX) · NOVO NORDISK A S (NVO) · Praxis Precision Medicines, Inc. (PRAX) · BIOCRYST PHARMACEUTICALS INC (BCRX) · Abivax S.A. (ABVX) · ALNYLAM PHARMACEUTICALS, INC. (ALNY) · BIOGEN INC. (BIIB) · BELITE BIO, INC (BLTE).

Recent 8-K filings

FiledItemsSource
Nov 17, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Oct 28, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 7, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Travere Therapeutics, Inc. (TVTX) · Track Record: how the signals scored · Practice timing on BSX

One email a week: the week’s new filings and research. Subscribe free

← BSM  ·  BSY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.